Keryx Biopharma (KERX)
H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Keryx Biopharma today and set a price target of $9. The company’s shares closed yesterday at $3.03, close to its 52-week low of $2.74.
“Valuation compelling. Keryx stock price has pulled back since the merger was announced in June, losing 33% of its value versus the XBI Biotech index losing only 9%. However we see only improving fundamentals as Auryxia revenues continue to improve QoQ.”
According to TipRanks.com, Kolbert ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.2% and a 37.3% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Coherus Biosciences.
Keryx Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $9.
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Histogenics today and set a price target of $1.20. The company’s shares closed yesterday at $0.54, close to its 52-week low of $0.50.
“We have updated our model to reflect the reported 3Q18 financials. For 2018, we project no revenues and a net loss of $0.42 per share. We note that the company reported cash and cash equivalents of $5.2M at the end of 3Q18 and raised $15.4M net of fees from an equity offering in October, which we believe is sufficient to maintain operations into 3Q19. Due to the associated dilution, we are lowering our 12-month price target for HSGX down to $1.20 per share, down from $2.00.”
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 2.2% and a 35.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
Currently, the analyst consensus on Histogenics is a Strong Buy with an average price target of $2.33.
Kala Pharmaceuticals Inc (KALA)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kala Pharmaceuticals Inc, with a price target of $15. The company’s shares closed yesterday at $7.65, close to its 52-week low of $7.16.
“We note that INVELTYS is the first and only FDA-approved corticosteroid eye drop with a BID dosing regimen to be used after ocular surgeries. Reimbursement by commercial payors could be obtained throughout 2019, in our view, and Medicare coverage could follow in 2020. We have adjusted our 2019 revenue projections lower due to the time needed for commercial payors to start covering INVELTYS. In addition, due to recent late-stage trial initiations of competitor candidates in dry eye, we have more than halved our projected peak annual sales of $1B, while maintaining the probability of success at 65%. Accordingly, our estimated enterprise value of the firm has decreased from $1.1B to $570M. Excluding $75M debt, this leads to a market value of the firm at $495M.”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.6% and a 31.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Fennec Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kala Pharmaceuticals Inc with a $32.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.